Upcoming Data For Athersys Crucial, But Not In Terms Of Immediate Share Price
- Topline data due late April for Athersys', Pfizer's phase 2 trial of MultiStem for ulcerative colitis are critical, but immediate effect on the share price of ATHX may be muted.
- The real move may be delayed until the next tranche of data to be released 8 weeks later, and possibly until Pfizer decides how to proceed.
- Traders anticipating the upcoming data should be prepared for a delay in any sustained move until somewhere between July-October.
- On Moxie, Oxytocin, And Shkreli: The Case For Retrophin
- Fundamentally And Technically, Fresenius Wins Big Over DaVita
- A Comprehensive Overview Of Active Electroporation Cancer Trials
- Is Car Charging Group The Bubba Gump Shrimp Of EV Charging?
- Evolution Of Biotech Industry: A Quick Look At Diversification, Divesting And Partnering
- New Trends In Healthcare And Wellness: New Technologies, Savvy Consumers And Disruptive Players
- Ophthalmology Market: Healthy Growth, But Only A Few Companies Possess Robust Drug Pipelines
- The Specialty Eateries Sector Tastes Good
- Government Money Is Killing Electric Cars: Car Charging Group Vs. Ecotality
- It's A Mobile Economy
- Pain Therapeutics - Another Oxycodone Remix
- Education In China Is A Sure Bet